CN110917287A - 一种药用植物提取物 - Google Patents
一种药用植物提取物 Download PDFInfo
- Publication number
- CN110917287A CN110917287A CN201911170090.8A CN201911170090A CN110917287A CN 110917287 A CN110917287 A CN 110917287A CN 201911170090 A CN201911170090 A CN 201911170090A CN 110917287 A CN110917287 A CN 110917287A
- Authority
- CN
- China
- Prior art keywords
- garlic
- extract
- soluble
- medicinal plant
- intravenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000419 plant extract Substances 0.000 title claims abstract description 14
- 240000002234 Allium sativum Species 0.000 claims abstract description 48
- 235000004611 garlic Nutrition 0.000 claims abstract description 46
- 239000000284 extract Substances 0.000 claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 238000001990 intravenous administration Methods 0.000 claims abstract description 17
- 201000011510 cancer Diseases 0.000 claims abstract description 16
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 12
- 238000010253 intravenous injection Methods 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 238000002347 injection Methods 0.000 claims abstract description 8
- 239000007924 injection Substances 0.000 claims abstract description 8
- 239000007928 intraperitoneal injection Substances 0.000 claims abstract description 4
- 230000002601 intratumoral effect Effects 0.000 claims abstract description 4
- 230000000813 microbial effect Effects 0.000 claims abstract description 3
- 239000006000 Garlic extract Substances 0.000 claims description 21
- 235000020706 garlic extract Nutrition 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 244000223014 Syzygium aromaticum Species 0.000 claims description 8
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- -1 ll Species 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000000861 blow drying Methods 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 claims 1
- 229940029982 garlic powder Drugs 0.000 claims 1
- 229940093181 glucose injection Drugs 0.000 claims 1
- 239000012676 herbal extract Substances 0.000 claims 1
- 229940090044 injection Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 208000032839 leukemia Diseases 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及到药用植物提取物技术领域,尤其为一种药用植物提取物,用于治疗癌症,二型糖尿病及传染病。本发明涉及到药用生大蒜有机脂溶性提取物具有治疗癌症,二型糖尿病及传染病的作用。用生大蒜有机脂溶性提取物直接作用于体外细胞抗癌实验,腹腔内注射或者肿瘤内注射的动物抗癌实验实验,生大蒜有机脂溶性提取物有直接杀死癌细胞症细胞的作用,本发明描述生大蒜有机脂溶性提取物的提取方法及静脉注射液的制备方法及流程,本发明描述生大蒜有机脂溶性提取物制备成静脉制剂用于静脉给药、腹腔注射、肿瘤内注射,以治疗恶性肿瘤、白血病、乙型糖尿病和微生物感染性疾病。
Description
技术领域
本发明涉及药用植物提取物技术领域,尤其是一种药用植物提取物。
背景技术
恶性肿瘤、白血病、乙型糖尿病和抗药细菌感染仍旧是人类疑难病症,没有高效治疗方案。
世界卫生组织(WHO)报告每六人中就有一位死于癌症,根据美国国家癌症研究所估计在2017年里有1,688,780新发癌症病例及600,920病死于癌症,据学术界不完全估计,在中国境内每年有多于300万病人死于癌症,据估计在中国每年多于100万人死于糖尿病,多于200万人死于感染性疾病,在1990年,美国国家癌症研究所总结大蒜可能具有防治肿瘤的作用,但大量动物及人体实验结果表明通过口服大蒜的各种制剂并不能防治癌症,到目前为止大蒜或大蒜提取物仍旧没有被世界上任何医疗监管部门及医院列为药用物质,主要原因是迄今没有任何令人信服的研究证据支持口服大蒜及提取物的疗效。本发明是将生大蒜有机脂溶性提取物制成静脉制剂通过注射方式入体,以达到前所未有的对癌症的疗效,直接通过静脉给药途径可以将生大蒜有机脂溶性提取物直接作用于病源细胞达到疗效。
现在治疗细菌感染引起的传染病,有很多不同的抗菌素之类的药物,但是由大量乱用抗生素,耐药菌株大量产生,不同的细菌感染引起的疾病,比如,肺炎,结核病,淋病现在对常用药都产生了抗药性,病毒感染引起的疾病,比如上呼吸道感染,现在主要是对症治疗以减少并发症,但是病毒本身对药物产生耐药性,近年来,有些研究者用有些食物来提高或者刺激人体免疫力来防治传染病,虽然有大量的研究,但并没有根据证明这些食物包括大蒜可以防治微生物引起的传染病。治疗微生物感染引起的传染病,现在广泛应用的是抗菌素,而由于这些抗菌的过度使用,近几十年以内,由于抗药性的原因,有很多超级细菌的产生,已经成为一个严重的问题,本发明是将生大蒜有机脂溶性提取物制成静脉制剂通过注射方式入体,以达到前所未有的对微生物,包括超级细菌引起的感染病的疗效。
糖尿病,尤其是二型糖尿病已经成为世界上的主要问题,每年全球都有数亿新发病例。有报道指岀,食用大蒜可以防治糖尿病,本发明是将生大蒜有机脂溶性提取物制成静脉制剂通过注射方式入体,以达到前所未有的对严重二型糖尿病的治疗。
发明内容
本发明的目的是为了解决现有技术中存在的缺点,而提出的一种药用植物提取物,来达到治疗癌症、传染病以及糖尿病。
为了实现上述目的,本发明采用了如下技术方案:
一种药用植物提取物,用于治疗癌症,二型糖尿病及传染病。
优选的,所述药用植物提取物是有机脂溶生大蒜提取物。
优选的,所述药用植物所可用生大蒜含所有大蒜种类。
优选的,所述有机脂溶生大蒜提取物治疗癌症的剂型可是粉状或液体,然后制成静脉注射液,用药途径可以是静脉给药,肿瘤内注射及腹腔内注射。
优选的,所述有机脂溶生大蒜提取物治疗传染病的剂型可是粉状或液体,然后制成静脉注射液,用药途径是静脉给药。
优选的,所述有机脂溶生大蒜提取物治疗二型糖尿病的剂型可是粉状或液体,然后制成静脉注射液,用药途径是静脉给药。
优选的,所述静脉注射液制备步骤:
S1,先将大蒜瓣儿剥皮;
S2,大蒜瓣及所有后续容器全部用清水,蒸馏水清洗,然后全部用酒精侵泡十分钟以上消毒杀菌,再用水清洗;
S3,将大蒜瓣及其湿重多倍的无菌蒸馏水加入破壁机,搅碎搅拌;
S4,将大蒜汁过滤去渣呈乳白色浑浊液,离心,取上清液;
S5,将清亮上清液用微米孔径过滤膜过滤去渣包括细菌,得到大蒜水溶性提取液,备用;
S6,将同体积1:1氯仿/甲醇加入大蒜水溶性提取液中,高速涡旋混合,然后加同体积4:5 1-丁醇/50mM NaCl溶液,再高速涡旋混合,形成混合液;
S7,将混合液搅拌,然后室温离心,小心抽出最淡黄色脂溶层,转移到清洁无菌的玻璃管内,用吹干成粉末,得到大蒜脂溶性提取物;
S8,将大蒜脂溶性粉状提取物溶解于100%二甲基亚矾,然后,根据临床需要制成静脉注射液。
与现有技术相比,本发明具有以下有益效果:
1、本发明涉及到药用生大蒜有机脂溶性提取物具有治疗癌症,二型糖尿病及传染病的作用,用生大蒜有机脂溶性提取物直接作用于体外细胞抗癌实验,腹腔内注射或者肿瘤内注射的动物抗癌实验实验,生大蒜有机脂溶性提取物有直接杀死癌细胞症细胞的作用,本发明描述生大蒜有机脂溶性提取物的提取方法及静脉注射液的制备方法及流程,本发明描述生大蒜有机脂溶性提取物制备成静脉制剂用于静脉给药、腹腔注射、肿瘤内注射,以治疗恶性肿瘤、白血病、乙型糖尿病和细菌感染。
2、本发明中生大蒜有机脂溶性提出物静脉用药治疗二型糖尿病:到目前为止,有很多研究表明口服大蒜,或者大蒜提取物可以控制二型糖尿病,本发明是用生大蒜有机脂溶性提出物静脉用药来治疗二型糖尿病;生大蒜有机脂溶性提出物静脉用药治疗微生物感染引起的疾病:口服大蒜提取物或者食用大蒜可以刺激人体免疫系统达到抗菌作用,很多实验室研究证明食用大蒜有抗菌,抗真菌,抗病毒的作用,本发明第一次应用生大蒜有机脂溶性提出物静脉用药来治疗微生物感染引起的疾病。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
含有生大蒜有机脂溶性提取物抗癌活性验证:
1.在96孔细胞培养盘中铺布人癌细胞株,如海拉宫颈癌细胞,密度15%左右,生长24小时,37度,5%CO2;
2.加大蒜提取液,稀释1:200-1:2000倍,共培养24小时;
3.根据厂家流程加CCK8活细胞检测液,和不加大蒜提取液对照相比,检测癌细胞存活率;
4.高效杀癌制品应该达到1:2000稀释后仍有100%的杀伤率。
实施例2
小鼠恶性肿瘤模型验证:
1.8只小白鼠,体重15-20;
2.每只腹腔注射10e6细胞培养出来的sarcoma180(S180)细胞;
3.第二天随机选择4只腹腔注射1毫升第13项所述的大蒜水提取液,1:9稀释液;
4.每天重复一次同样剂量注射,直到另外4只不注射大蒜提取液的对照小鼠长腹水死光,一般不超过21天;
5.生大蒜有机脂溶性腹腔内注射的小鼠全部存活并没有观察到的副作用;
6.对照组的小鼠全部有腹水而死亡。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (8)
1.一种药用植物提取物,用于治疗癌症,二型糖尿病及微生物感染性疾病。
2.根据权利要求1所述的药用植物提取物,其特征在于:所述药用植物提取物是有机脂溶生大蒜提取物。
3.根据权利要求1所述的药用植物提取物,其特征在于:所述药用植物所可用生大蒜含所有大蒜种类。
4.根据权利要求1和2所述的药用植物提取物,其特征在于:所述有机脂溶生大蒜提取物治疗癌症的剂型可是粉状或液体,然后制成静脉注射液,用药途径可以是静脉给药,肿瘤内注射及腹腔内注射。
5.根据权利要求1和2所述的药用植物提取物,其特征在于:所述有机脂溶生大蒜提取物治疗传染病的剂型可是粉状或液体,然后制成静脉注射液,用药途径是静脉给药。
6.根据权利要求1和2所述的药用植物提取物,其特征在于:所述有机脂溶生大蒜提取物治疗二型糖尿病的剂型可是粉状或液体,然后制成静脉注射液,用药途径是静脉给药。
7.根据权利要求4、5和6所述的药用植物提取物,其特征在于:所述静脉注射液制备步骤:
S1,先将大蒜瓣儿剥皮;
S2,大蒜瓣及所有后续容器全部用清水,蒸馏水清洗,然后全部用酒精侵泡十分钟以上消毒杀菌,再用水清洗;
S3,将大蒜瓣及其湿重多倍的无菌蒸馏水加入破壁机,搅碎搅拌;
S4,将大蒜汁过滤去渣呈乳白色浑浊液,离心,取上清液;
S5,将清亮上清液用微米孔径过滤膜过滤去渣包括细菌,得到大蒜水溶性提取液,备用;
S6,将同体积1:1氯仿/甲醇加入大蒜水溶性提取液中,高速涡旋混合,然后加同体积4:5 1-丁醇/50mM NaCl溶液,再高速涡旋混合,形成混合液;
S7,将混合液搅拌,然后室温离心,小心抽出最淡黄色脂溶层,转移到清洁无菌的玻璃管内,吹干成粉末,得到脂溶性生大蒜提取物;
S8,将脂溶性生大蒜粉状提取物溶解于100%二甲基亚矾,然后,根据临床需要制成静脉注射液。
8.根据权利要求7所述的药用植物提取物,其特征在于,所述有机脂溶性生大蒜提取物和二甲基亚矾根据不同的临床需要加入以下标准静脉用药溶液中,配为标准静脉用制济:90%生理盐水(0.9NaCl)、乳酸林格氏液、5%葡萄糖注射液和45%生理盐水(0.45NaCl),以上标准静脉用制剂的大蒜脂溶性提取物及二甲基亚矾的浓度一般不超过5%。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/577,605 | 2019-09-20 | ||
US16/577,605 US11167002B2 (en) | 2019-08-26 | 2019-09-20 | Pharmaceutical composition for the treatment of malignant neoplasms including sarcoma, cancers of liver, lung, bladder, blood and cervical, treatment of infectious diseases and type 2 diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110917287A true CN110917287A (zh) | 2020-03-27 |
Family
ID=69850982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911170090.8A Pending CN110917287A (zh) | 2019-09-20 | 2019-11-26 | 一种药用植物提取物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11167002B2 (zh) |
EP (1) | EP3795165A1 (zh) |
CN (1) | CN110917287A (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220118044A1 (en) * | 2020-10-16 | 2022-04-21 | David Xiage Gan | Injectable garlic formulation and a method of using the injectable garlic formulation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999021008A1 (en) * | 1997-10-23 | 1999-04-29 | Pharmaprint, Inc. | Pharmaceutical grade garlic |
JP2005089419A (ja) * | 2003-09-19 | 2005-04-07 | Noevir Co Ltd | ニンニクエキス |
US8778421B1 (en) * | 2013-01-11 | 2014-07-15 | Behnam Azizkhani | Herpes treatment |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100506962C (zh) * | 2005-12-09 | 2009-07-01 | 郭涛 | 大蒜油的精制方法及其乳剂和固体脂质纳米粒的制备工艺 |
-
2019
- 2019-09-20 US US16/577,605 patent/US11167002B2/en active Active
- 2019-11-26 CN CN201911170090.8A patent/CN110917287A/zh active Pending
-
2020
- 2020-09-04 EP EP20194572.2A patent/EP3795165A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999021008A1 (en) * | 1997-10-23 | 1999-04-29 | Pharmaprint, Inc. | Pharmaceutical grade garlic |
JP2005089419A (ja) * | 2003-09-19 | 2005-04-07 | Noevir Co Ltd | ニンニクエキス |
US8778421B1 (en) * | 2013-01-11 | 2014-07-15 | Behnam Azizkhani | Herpes treatment |
Non-Patent Citations (1)
Title |
---|
ZHIMING LI等: "A novel therapeutic anticancer property of raw garlic extract via injection but not ingestion", 《CELL DEATH DISCOVERY》 * |
Also Published As
Publication number | Publication date |
---|---|
US11167002B2 (en) | 2021-11-09 |
EP3795165A1 (en) | 2021-03-24 |
US20210077561A1 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104829738B (zh) | 草叶马尾藻多糖提取物在改善肠道菌群防治糖尿病中的应用 | |
CN101690813B (zh) | 一种鸡新城疫浓缩冻干卵黄抗体复合制剂及其制备工艺 | |
CN110917287A (zh) | 一种药用植物提取物 | |
CN111329982B (zh) | 小柴胡颗粒联合磷酸氯喹的新应用 | |
CN109568335B (zh) | 紫菜多糖在干预秀丽隐杆线虫衰老中的应用 | |
CN103305567A (zh) | 卡介菌复合多糖及其制备方法和用途 | |
CN102232957B (zh) | 3-乙酰氧基-8,24-羊毛甾二烯-21-酸在制备预防、治疗肝癌或乳腺癌药物中的用途 | |
CN101919878A (zh) | 短棒状杆菌在制备治疗新型甲型h1n1流感病毒感染药剂中的应用 | |
CN100358535C (zh) | 一种分枝杆菌多糖复合物及其制备方法 | |
CN101407556B (zh) | 虫草多糖注射剂的制备方法及在癌症方面的用途 | |
CN101041686A (zh) | 林蛙抗癌肽及其制备方法 | |
CN105434895A (zh) | 一种天麻景天膏及其制备方法 | |
TW200412989A (en) | Gamma delta T cell immunoactivity enhancers containing extract of Lentinus edodes mycelium | |
CN113499328B (zh) | 甘草查尔酮a在制备抗艰难梭菌感染药物中的应用 | |
CN113694096B (zh) | 一种甘草提取物及其制备方法和应用 | |
CN107137652A (zh) | 草果油的新用途 | |
RU2505305C1 (ru) | Способ лечения респираторных болезней телят | |
CN103356813B (zh) | 一种了哥王胶囊 | |
CN102078529B (zh) | 一种用于治疗小儿感冒的中药制剂 | |
CN106265630A (zh) | 穗花杉双黄酮在研发治疗肺炎药物中的应用 | |
CN1939440A (zh) | 一种具有收敛止血、止痢解毒功能的兽用药剂及其制法 | |
CN101120958A (zh) | 一种治疗肝癌、白血病的药物制剂与其生产工艺 | |
CN101229227B (zh) | 一种水剂药物组合物及其制备方法与应用 | |
CN112294796A (zh) | 安五脂素在抗水产动物嗜水气单胞菌感染中的应用 | |
CN116270866A (zh) | 一种抗病毒口服液的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200327 |